WALTHAM,
Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced that members of its management team will
participate in two upcoming investor conferences:
- A fireside chat at the Guggenheim 6th Annual Biotechnology
Conference at 10:00 a.m. ET on Thursday,
February 8, 2024 in New York,
NY.
- A fireside chat at the Citi 2024 Virtual Oncology Leadership
Summit at 2:00 p.m. ET on Wednesday,
February 21, 2024.
A live webcast of the fireside chats can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the events will also be available for a limited
time.
About Syndax
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective inhibitor of the menin–KMT2A binding
interaction, and axatilimab, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor. For more information,
please visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-302051306.html
SOURCE Syndax Pharmaceuticals, Inc.